Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Severe Acute Gut GvHD
NCT04280471Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in Acute Graft-Versus-Host Disease (aGvHD), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events at 6 months, Episodes of microbial bloodstream infection attributed to FMT at 7 days and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04280471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280471.